Jeff Sharman, MD

Bispecific antibodies, CAR T therapy, and targeted drugs transform non-Hodgkin lymphoma care, with earlier use and MRD-guided strategies poised to boost outcomes.

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, while CAR T and pivotal trials reshape strategy.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.

ALPHA3 highlights off-the-shelf allogeneic CAR T in community clinics, reducing leukapheresis hurdles and speeding up delivery.

Phase 2 ALPHA3 shows cema-cel in MRD-positive large B-cell lymphoma has no CRS/ICANS so far, enabling outpatient consolidation with manageable adverse effects.

Interim ALPHA3 data show cema-cel clears ctDNA MRD in high-risk DLBCL after frontline therapy, prompting continued study of consolidation CAR T.

Blood MRD reveals hidden DLBCL after chemo; ALPHA3 trials off-the-shelf CD19 CAR T, boosting MRD clearance with low toxicity.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).